aTYR PHARMA INC (ATYR)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, aTYR PHARMA INC reported revenue of $190.0K, down 19.1% from the prior year. The company ran a net loss, with a net margin of -39009.5%.
Key ratios (FY2025)
-40856.3%
Operating margin
-39009.5%
Net margin
-109.8%
Return on equity
-19.1%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190.0K | $235.0K | $353.0K | $10.39M | $0 | $10.46M | $422.0K | — | — | — |
| Operating Income | -$77.63M | -$67.91M | -$54.92M | -$46.40M | -$34.02M | -$15.91M | -$22.98M | -$32.82M | -$47.15M | -$57.94M |
| Net Income | -$74.12M | -$64.02M | -$50.39M | -$45.34M | -$33.77M | -$16.22M | -$16.22M | -$34.52M | -$48.21M | -$57.85M |
| EPS (Diluted) | $-0.80 | $-0.86 | $-0.94 | $-1.60 | $-1.77 | $-1.77 | — | — | — | — |
| Total Assets | $93.00M | $96.83M | $120.65M | $95.79M | $115.54M | $38.73M | $36.19M | $52.75M | $89.36M | $80.52M |
| Shareholders' Equity | $67.48M | $70.02M | $90.66M | $71.46M | $109.30M | $31.65M | $21.19M | $33.65M | $64.25M | $62.80M |
| Cash & Equivalents | $10.74M | $11.05M | $22.54M | $9.98M | $2.34M | $16.95M | $9.21M | $22.96M | $21.09M | $38.39M |
| Operating Cash Flow | -$61.99M | -$69.12M | -$33.22M | -$41.89M | -$33.08M | -$15.30M | -$20.01M | -$31.06M | -$42.36M | -$52.86M |
| Capital Expenditures | $77.0K | $65.0K | $4.21M | $1.64M | $192.0K | $202.0K | $79.0K | $594.0K | $1.31M | $600.0K |
| Shares Outstanding | 98.03M | 84.04M | 63.29M | 29.50M | 27.79M | 11.02M | 3.89M | 2.19M | 29.79M | 23.74M |